Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06062420 · ClinicalTrials.gov registry record · Phase 2

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

A Phase 2 study of Neoplasms, Head and Neck, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
316
Enrollment target
20
Study locations

NCT06062420 is a Phase 2 study of Neoplasms, Head and Neck that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 316 participants, roughly in line with the 331-participant average among 4 other Neoplasms, Head and Neck trials with a reported enrollment target. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06062420, a Phase 2 study of Neoplasms, Head and Neck, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
316 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

Conditions Studied

Neoplasms, Head and Neck

Interventions

  • DRUG Dostarlimab
  • DRUG Remzistotug
  • DRUG Belrestotug
  • DRUG Nelistotug

Study Locations (20)

Other

  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Capital Federal
  • GSK Investigational Site - Ciudad Autonoma de Bueno
  • GSK Investigational Site - Córdoba
  • GSK Investigational Site - Florida
  • GSK Investigational Site - Mendoza
  • GSK Investigational Site - San Juan
  • GSK Investigational Site - Santa Fe
  • GSK Investigational Site - Santo André
  • GSK Investigational Site - São Paulo
  • GSK Investigational Site - São Paulo

Alberta

  • GSK Investigational Site - Calgary
  • GSK Investigational Site - Edmonton

Ontario

  • GSK Investigational Site - Toronto
  • GSK Investigational Site - Toronto

Connecticut

  • GSK Investigational Site - New Haven

Iowa

  • GSK Investigational Site - Iowa City

Missouri

  • GSK Investigational Site - St Louis

Ohio

  • GSK Investigational Site - Columbus

Wisconsin

  • GSK Investigational Site - Milwaukee

Trial Details

FieldValue
Enrollment Target 316 participants
Start Date 2023-11-14
Est. Completion 2027-07-22
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06062420

The ClinicalTrials.gov registry entry for NCT06062420 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 331-participant average among 4 other Neoplasms, Head and Neck trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms, Head and Neck appearing as the primary indexed condition, and to 4 interventions - of which Dostarlimab is the first listed.

NCT06062420 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Alberta, Ontario.

Frequently Asked Questions

What is clinical trial NCT06062420 about?

NCT06062420 is a clinical study titled "A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202". The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).

What is the current status of trial NCT06062420?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 316 participants. The study started on 2023-11-14. Estimated completion is 2027-07-22.

What conditions does trial NCT06062420 study?

This clinical trial studies the following conditions: Neoplasms, Head and Neck.

What interventions are being tested in trial NCT06062420?

The interventions under investigation include: Dostarlimab (DRUG), Remzistotug (DRUG), Belrestotug (DRUG), Nelistotug (DRUG).

Who is sponsoring clinical trial NCT06062420?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06062420 being conducted?

This trial has 20 study locations across Connecticut, Iowa, Missouri, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms, Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms, Head and Neck

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.